Dallas, TX, October 22, 2010 --(PR.com
)-- ReportsandReports announce The Cancer Market Outlook to 2015: Competitive landscape, market size, pipeline analysis, and growth opportunities Market Research Report in its Store.
Browse complete Report at: The Cancer Market Outlook to 2015: Competitive landscape, market size, pipeline analysis, and growth opportunities
Global cancer prevalence rates are on the rise owing to an aging population, changing lifestyle and increasing pollution. Prevalence data is significantly influenced by the increasing diagnosis and survival rates across the global market.
The global cancer market is becoming increasingly competitive, with two therapeutic classes namely antineoplastics and cytostatic hormonal treatments dominating this sector. Collectively, the top 10 products in the global cancer market accounted for majority of the revenue in 2009.
Oncology has become one of the major focus areas for pharmaceutical and biotechnology companies because of a high number of unmet needs for improved treatments in different types of cancer. In 2009, around 40,000 Phase I, II and III trials were listed on ClinicalTrials.gov, and approximately 40% of these were related to cancer.
Targeted therapies are revolutionizing the paradigm of cancer treatment and are likely to be used in most cancer patients in the next 10 years. Due to the high incidence and subsequent potential for market success, breast cancer and NSCLC continue to drive high levels of R&D (along with niche indications such as NHL, RCC, CML, and prostate cancer).
Another factor that plays a major role for the growth in the cancer therapy market is expansion of the target indications. Most of the blockbuster drugs were launched for a narrow indication, and were later approved for other indications. A classic example is imatinib, which was first approved by the FDA in 2001 for the treatment of CML and later was expanded to around nine different indications.
Regardless of indication, the key challenge in ensuring the commercial success of pipeline drugs is to ascertain their integration into current treatment regimens either in combination with existing therapies or by demonstrating significant superiority over current treatments. Pricing risk remains the key investment concern in cancer. Moreover, the level of scrutiny by payors regarding the cost-effectiveness of cancer treatments has further intensified in the recent years.
Key Features of this report
Epidemiological analysis and forecast prevalence of the major cancer indications between 2009-15 including lung, breast, colorectal, and ovarian cancer markets.
Forecasts and analysis of the major products in the cancer market between 2009-15 spread across the major indications and classes of treatments.
Overview of key events in the global cancer market that have impacted treatment trends and sales potential across the major cancer indications.
Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios.
Detailed analysis across major classes of cancer treatments including antineoplastics and cytotoxic hormone therapies.
Detailed analysis of the clinically differentiated products in the cancer pipeline by indication and sales forecast of key R&D pipeline products in the global cancer market.
Key Benefits of this report
Develop insight into patient potential with the report’s coverage of major indications in the cancer segment, the seven largest geographic pharmaceutical markets and the 10 largest companies active in the cancer segment today
Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in the cancer marketplace
Gain up-to-date competitive intelligence across the cancer indications and understand the major issues affecting key pharmaceutical/biotech players
Understand which indications have the greatest potential to provide franchise growth, and how pharmaceutical companies are attempting to exploit these opportunities
Compare the franchises of top pharmaceutical marketers across major indications, and understand how market share of leading companies will change over the next 6 years
Use head-to head comparisons of the leading cancer pipeline compounds to understand which companies will have a presence among key indications over the next 6 years
Browse all Healthcare Market Research Reports
Browse all Business Insights Market Research Reports
Browse all Newly Published Market Research Reports http://www.reportsandreports.com/LatestReport.aspx
Original Source: The Cancer Market
Buy Now: Research
The Cancer Market Outlook To 2014: Competitive landscape, market size, pipeline analysis and growth opportunities
The Cancer Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
The Vaccines Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts
The Pain Management Market Outlook To 2014: Competitive landscape, pipeline analysis and growth opportunities
The Genitourinary Market Outlook to 2015: Competitive landscape, global market analysis and pipeline analysis
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
7557 Rambler road,
Suite 727, Dallas, TX 75231